Effect of Nicotinamide Mononucleotide Concentration in Human Milk on Neurodevelopmental Outcome: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study
- PMID: 38201974
- PMCID: PMC10780616
- DOI: 10.3390/nu16010145
Effect of Nicotinamide Mononucleotide Concentration in Human Milk on Neurodevelopmental Outcome: The Tohoku Medical Megabank Project Birth and Three-Generation Cohort Study
Abstract
(1) Background: Breast milk is the only source of nutrition for breastfed infants, but few studies have examined the relationship between breast milk micronutrients and infant neurodevelopmental outcome in exclusively breastfed infants. The aim of this study was to characterize the association between nicotinamide adenine dinucleotide (NAD)-related compounds in the breast milk of Japanese subjects and infant neurodevelopmental outcome. (2) Methods: A total of 150 mother-child pairs were randomly selected from the three-generation cohort of the Tohoku Medical Megabank in Japan. Infants were exclusively breastfed for up to 6 months. Breast milk was collected at 1 month postpartum, and the quantity of NAD-related substances in the breast milk was quantified. The mothers also completed developmental questionnaires at 6, 12, and 24 months. The relationship between the concentration of NAD-related substances in breast milk and developmental indicators was evaluated via ordinal logistic regression analysis. (3) Results: Nicotinamide mononucleotide (NMN) was quantified as the major NAD precursor in breast milk. The median amount of NMN in the breast milk was 9.2 μM. The NMN concentration in breast milk was the only NAD-related substance in breast milk that showed a significant positive correlation with neurodevelopmental outcome in infants at 24 months. (4) Conclusions: The results suggest that NMN in human milk may be an important nutrient for early childhood development.
Keywords: breast milk; cohort study; infants; neurodevelopmental outcome; nicotinamide mononucleotide.
Conflict of interest statement
Breast milk samples and accompanying data were provided to Meiji Co., Ltd., from Tohoku Medical Megabank. The funder, AMED, had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Figures
Similar articles
-
Simultaneous quantitation of nicotinamide riboside, nicotinamide mononucleotide and nicotinamide adenine dinucleotide in milk by a novel enzyme-coupled assay.Food Chem. 2017 Apr 15;221:161-168. doi: 10.1016/j.foodchem.2016.10.032. Epub 2016 Oct 11. Food Chem. 2017. PMID: 27979136
-
Towards personalized nicotinamide mononucleotide (NMN) supplementation: Nicotinamide adenine dinucleotide (NAD) concentration.Mech Ageing Dev. 2024 Apr;218:111917. doi: 10.1016/j.mad.2024.111917. Epub 2024 Feb 29. Mech Ageing Dev. 2024. PMID: 38430946
-
The Safety and Antiaging Effects of Nicotinamide Mononucleotide in Human Clinical Trials: an Update.Adv Nutr. 2023 Nov;14(6):1416-1435. doi: 10.1016/j.advnut.2023.08.008. Epub 2023 Aug 22. Adv Nutr. 2023. PMID: 37619764 Free PMC article. Review.
-
Reversal of endothelial dysfunction by nicotinamide mononucleotide via extracellular conversion to nicotinamide riboside.Biochem Pharmacol. 2020 Aug;178:114019. doi: 10.1016/j.bcp.2020.114019. Epub 2020 May 8. Biochem Pharmacol. 2020. PMID: 32389638
-
Nicotinamide mononucleotide (NMN) as an anti-aging health product - Promises and safety concerns.J Adv Res. 2021 Aug 11;37:267-278. doi: 10.1016/j.jare.2021.08.003. eCollection 2022 Mar. J Adv Res. 2021. PMID: 35499054 Free PMC article. Review.
References
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources